You are here

Biogen Makes Play for Big Stake in Samsung Bioepis

Puts down $700 million to buy nearly 50% of Samsung.

In a move analysts of the biosimilars market have been looking for, Biogen decided to jump into a pool with both feet that it merely stuck its toe in in 2011. Biogen slapped down $700 million in its bid to buy 49.9% of Samsung Bioepis, Endpoints News reports.

Apparently, the move springs from a change in CEOs. Back in 2011, it was George Scangos. Today it is Michel Vounatsos. “This option allows us to increase our ownership share in a leading biosimilar company at what we believe are attractive terms,” Vounatsos tells Endpoints News. “We look forward to building an important relationship with Samsung BioLogics.”

Source: Endpoints News

More Headlines

Agency says products for sexual enhancement, weight loss, and bodybuilding have hidden drugs and chemicals.
A meta-analysis that included 18 million participants found no protection from heart disease or stroke.
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.
Some of that can be chalked up to the differences in cost of living from place to place, but not all.
Health plans expected to continue pushing for value-based payment arrangements.
One of the proposed changes makes remote patient monitoring an allowable cost.
European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab.
The move comes even though some of the pharma company’s rivals have promised to raise prices only once a year.